• HOME
  • Products
  • in vivo siRNA transfection kit "AteloGene® Local Use Quick Gelation","AteloGene® Local Use" & "AteloGene® Systemic Use "

in vivo siRNA transfection kit for mice

in vivo siRNA transfection kit
"AteloGene® Local Use Quick Gelation",
"AteloGene® Local Use" & "AteloGene® Systemic Use "


print

Background

This product is a kit for delivering siRNA into animal tissues by local or systemic administration in mice and then efficiently introducing it into the cells.

 


AteloGene® Local Use
Quick Gelation
(Cat.#KOU-1492)    More

AteloGene

AteloGene® Local Use 
(Cat.#KOU-1392)
AteloGene® Systemic Use 
(Cat.#KOU-1393)


AteloGene® flyer download [PDF]

AteloGene® QG flyer download [PDF]



 
  Difference between "AteloGene® Local Use Quick Gelation" and  "AteloGene® Local Use"  and "AteloGene® Systemic Use"


AteloGene® Local Use Quick Gelation   AteloGene® Local Use & AteloGene® Systemic Use
Main features

Rapider gelation after administration.
Increased volume.

   More  

Controlled release effect at the administration site.
Or systemic administration.  

Package   15 administration*
   More 
10 administration*

*Calculated as 200µL/administration. Administration number is depending on target tissue.


 

Characteristics of Atelocollagen FAQ
Atelocollagen is a collagen solubilized by protease. Its physical properties are virtually identical to natural, unsolubilized collagen. Furthermore, atelocollagen has superior characteristics;----- More

Characteristics of Atelocollagen FAQ

 

Animation for understanding AteloGene®
RNA interference (RNAi) is a mechanism where fragments of double-strand ribonucleic acid (dsRNA) interfere with the expression of a specific gene whose sequence is complementary to the dsRNA. Recently, RNAi medicine that inhibit the expression of genes responsible for specific diseases, has been studied actively. However, the delivery of siRNA in vivo had become a big issue as siRNA is unstable in vivo.

KOKEN(Tokyo) developed a new siRNA delivery system, “AteloGene®”. This system is mediated by atelocollagen that is a solubilized collagen obtained by protease treatment, and transfects siRNA in vivo efficiently and safety with each local administration and systemic administration.

Mechanism of RNAi and AteloGene®

<Industrial property rights>
Concerning the technique of introducing the nucleic acid component using this kit and collagen, Dainippon Sumitomo Pharma Co., Ltd. and KOKEN Co., Ltd. has either obtained the patent or the patent is under application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to tests and researches. Other usage of this product may infringe the patent. Please pay attention in this regard.

This product is a kit for delivering siRNA into animal tissues by local or systemic administration in mice and then efficiently introducing it into the cells.

AteloGene® FlyerPDF

Animation for understanding AteloGene®
RNA interference (RNAi) is a mechanism in which fragments of double-strand ribonucleic acid (dsRNA) interfere with the expression of a specific gene whose sequence is complementary to the dsRNA. Recently, RNAi medicines, that inhibit the expression of genes responsible for diseases, have been studied actively. However, the delivery of siRNA in vivo had become a big issue because siRNA is unstable in vivo.

KOKEN(Tokyo) developed a new siRNA delivery system, “AteloGene®”. This system is mediated by atelocollagen that is a solubilized collagen obtained by protease treatment, and transfects siRNA in vivo efficiently and safety with each local administration and systemic administration.

Mechanism of RNAi and AteloGene®

<Industrial property rights>
Concerning the technique of introducing the nucleic acid component using this kit and collagen, Dainippon Sumitomo Pharma Co., Ltd. and KOKEN Co., Ltd. has either obtained the patent or the patent is under application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to tests and researches. Other usage of this product may infringe the patent. Please pay attention in this regard.

 

Principle

When mixed with synthetic siRNA at an appropriate concentration and ratio, atelocollagen, which is a major component of “AteloGene®” forms a complex appropriate for administration into the body. siRNA that is prepared into a complex with atelocollagen is efficiently delivered in vivo and introduced into the cells.

 

Features and Advantages

AteloGene® Local Use Quick Gelation, AteloGene® Local Use and AteloGene® Systemic Use

 Prolonged RNAi effect because atelocollagen, the main component of “AteloGene®”, forms complexes with siRNA/miRNA.
• Since “AteloGene®” is made from atelocollagen, it is nontoxic.

 Immediate administration to experimental animals by mixing the synthetic siRNA with “AteloGene®”.
 Efficient in vivo transfection of siRNA.
 The effect of RNAi of preventing degradation by RNase persists for a long time.
 “AteloGene®” has no toxicity, and its main component is atelocollagen that demonstrates high biological compatibility
 It is possible to choose “AteloGene® Local Use” for local administration or “AteloGene® Systemic Use” for systemic administration by injection to the tail vein
 Since “AteloGene® Local Use” for local administration is gelated in the body, siRNA is securely kept at the administration site
 Since “AteloGene® Systemic Use ” for systemic administration is not gelated in the body but circulated in the blood after injection into the tail vein, siRNA is efficiently delivered to the whole body

< Efficient delivery of siRNA to tissue > 

RNA present in various tissues at 24 hours following tail vein injection of atelocollagen complex containing 25 μg siRNA. Reference : Takeshita F, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. (2005) Proc Natl Acad Sci U S A. 102(34):12177-12182.


AteloGene

Application

Mechanism of siRNA transfection using “ AteloGene®Mechanism

< Local administration >
¡ Experimental example 1
Suppression of gene expression of subcutaneous tumor in mice
When luciferase siRNA (Luc siRNA) was administered using "AteloGene" against luciferase-expressing tumor cells that were subcutaneously grafted, the luciferase expression was inhibited at a larger degree compared with results observed after the administration of Luc siRNA alone.

 

¡ Experimental example 2

Stability of VEGF siRNA by intratumoral administration (Date source
: Dr. Y. Takei, Nagoya University, Japan)

AteloGene® Local Use was mixed with fluorescent labeled vascular endothelial growth factor (VEGF) siRNA and injected into subcutaneous tumor. Compared to VEGF siRNA alone, siRNA complexed with Atelogene® was efficiently delivered to tumor cells. Remarkably, VEGF-siRNA was present 8 days following administration and tumor growth was inhibited.
Reference : Takei Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. (2004) Cancer Res. 64(10):3365-3370.

 

¡ Experimental example 3


siRNA targeting Myostatin (Mst), an inhibitor of muscle differentiation, was injected intramuscularly in complex with Atelogene® Local Use. Muscular mass was significantly increased  in animals receiving Mst siRNA. Increased muscular mass was also observed following systemic injection of Mst specific siRNA/AteloGene® Systemic Use complexes
Reference : Kinouchi N, et al. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. (2008) Gene Ther. 15(15):1126-1130.

 

< Systemic administration >
Suppression of gene expression of generalized metastasized tumors in mice


When luciferase siRNA (Luc siRNA) was administered using "AteloGene®" against luciferase-expressing generalized metastasized tumor cells, the luciferase expression was more inhibited compared with the result observed after the administration of Luc siRNA alone.


 

Kit component

  AteloGene® Local Use Quick Gelation  AteloGene® Local Use & Systemic Use 
Cat. No. KOU-1492 KOU-1392, KOU-1493
Intended number of use 15 times of administration. 10 times of administration.
Content of kit  Content of AteloGene QG kit  New  Contents of kit
<Manuals>  AteloGene® Local Use QG ManualPDF New  AteloGene® Local Use & Systemic Use ManualPDF

 

 

 

<Procedure>

 

 Methods New

 Methods
KOU_1392_11 
<References>  Local Use Quick Gelation

 Systemic Use 

 Local Use 

<FAQ>  here  here



<NOTE>

# Storage
Storage temperature : 2-10°C(do not freeze)
Effective period: 5 years from the manufacturing date indicated on the box
Precautions for storage
  - Gelation and thermal denature occur in “AteloGene®” at a temperature higher than 20°C. Never use “AteloGene®” that was once gelated or thermally denatured.
  - Freezing “AteloGene®” causes bubbles in the mixture and the dispersion of components.  Never use “AteloGene®” that was once frozen.

# Precautions for use
1) This product is a reagent for research use only.Its application to the human body is strictly prohibited.Do not use it for any purposes other than for research purposes.
2) Be sure to read the instruction manual before use. The manufacturer is not liable for the results of usage by methods other than that described in the instruction manual. Depending on the type of siRNA, administration target or administration method, the expected effect may not always be obtained.

Agreement for purchasing “AteloGene®”

Please agree to  the following:

  (1)  I will not use “AteloGene®” for testing in human beings.
  (2)  I will not use “AteloGene®” for applying new patents without Koken's written consent.
  (3)  I will not use, deliver, sell, assign or let use “AteloGene®” to a person, or an organization which is beyond the scope of my control and responsibility without prior written consent from Koken

Please download and print the agreement form (PDF file) Please fax or e-mail the fill-ed out form to Cosmo Bio Co., Ltd. prior to placing your order with us.

Download the form
Product List

Product Name Cat# Quantity Price

AteloGene(R) Local Use Quick Gelation DataSheet ,

KOU-1492

1 KIT ¥81,300
$1084

AteloGene(R) Local Use DataSheet ,

KOU-1392

1 KIT ¥65,000
$867

AteloGene(R) Systemic Use DataSheet ,

KOU-1393

1 KIT ¥65,000
$867

To be used for research only. DO NOT use for human gene therapy or clinical diagnosis.



“in vivo siRNA transfection kit "AteloGene® Local Use Quick Gelation","AteloGene® Local Use" & "AteloGene® Systemic Use "” also belongs to the following categories.